Tanaka Junji
Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Hematol Oncol. 2021 Feb;39(1):11-19. doi: 10.1002/hon.2802. Epub 2020 Sep 21.
Natural killer (NK) cells have a potent cytotoxic activity against leukemia and lymphoma without recognition of human leukocyte antigen (HLA) molecules. Chimeric antigen receptor-engineered NK cells (CAR-NK cells) can be produced from the NK92 cell line, peripheral blood, cord blood, and induced pluripotent stem cells for immunotherapy of malignant tumor cells. Recently, the safety and efficacy of HLA-mismatched allogeneic cord blood-derived CD19 CAR-NK cell therapy for CD19-positive hematological malignancies have been reported. However, the durability of clinical effects has not been clarified. The characteristics of CAR-NK cells with a strong antileukemia/lymphoma effect and better proliferative capacity without severe adverse effects may be promising for overcoming intractable hematological malignancies as an off-the-shelf allogeneic cellular therapy.
自然杀伤（NK）细胞对白血病和淋巴瘤具有强大的细胞毒性活性，且无需识别人类白细胞抗原（HLA）分子。嵌合抗原受体工程化的NK细胞（CAR-NK细胞）可从NK92细胞系、外周血、脐带血和诱导多能干细胞中产生，用于恶性肿瘤细胞的免疫治疗。最近，已有关于HLA不匹配的同种异体脐带血来源的CD19 CAR-NK细胞疗法治疗CD19阳性血液系统恶性肿瘤的安全性和有效性的报道。然而，临床疗效的持久性尚未明确。具有强大抗白血病/淋巴瘤作用且增殖能力较好且无严重不良反应的CAR-NK细胞的特性，作为一种现成的同种异体细胞疗法，对于克服难治性血液系统恶性肿瘤可能具有前景。
